TENX — Tenax Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $26.05m
- -$72.26m
- 48
- 55
- 77
- 63
Annual income statement for Tenax Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.56 | 9.87 | 32.7 | 11.1 | 8.23 |
| Operating Profit | -8.56 | -9.87 | -32.7 | -11.1 | -8.23 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.39 | -9.85 | -33 | -11 | -7.71 |
| Net Income After Taxes | -8.39 | -9.85 | -33 | -11 | -7.71 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.39 | -9.85 | -33 | -11 | -7.71 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.39 | -9.85 | -33 | -11 | -7.71 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2,168 | -2,125 | -2,565 | -601 | -31 |